Effects of nicotinic stimulation on cognitive performance

Current Opinion in Pharmacology

Volumn 4, Issue 1, 2004, Pages 36-46

  Newhouse, Paul A ^a   Potter, Alexandra ^a   Singh, Abhay ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE; 3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE FUMARATE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; CLOZAPINE; DONEPEZIL; LEVODOPA; METHYLPHENIDATE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; PLACEBO;

ALZHEIMER DISEASE; ATTENTION; ATTENTION DEFICIT DISORDER; CHOLINERGIC STIMULATION; COGNITION; DRUG TARGETING; HUMAN; NONHUMAN; PARKINSON DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEIZURE; SMOKING; TASK PERFORMANCE;

ATTENTION; COGNITION; COGNITION DISORDERS; HUMANS; MODELS, BIOLOGICAL; NICOTINE; SMOKING; STIMULATION, CHEMICAL;

EID: 0742288775     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2003.11.001     Document Type: Review

References (110)

1. Gotti C. Fornasari D. Clementi F. Human neuronal nicotinic receptors Prog Neurobiol 53 1997 199-237
2. Lukas RJ: Neuronal nicotinic acetylcholine receptors. In The Nicotinic Acetylcholine Receptor: Current Views and Future Trends. Berlin: Springer Verlag; 1998:145-173.
3. Colquhoun L.M. Patrick J.W. Pharmacology of neuronal nicotinic acetylcholine receptor subtypes Adv Pharmacol 39 1997 191-220
4. Levin E.D. Nicotinic receptor subtypes and cognitive function J Neurobiol 53 2002 633-640
5. Greenland S. Satterfield M.H. Lanes S.F. A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch Drug Saf 18 1998 297-308
6. Joseph A.M. Norman S.M. Ferry L.H. Prochazka A.V. Westman E.C. Steele B.G. Sherman S.E. Cleveland M. Antonnucio D.O. Hartman N. McGovern P.G. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease N Engl J Med 335 1996 1792-1798
7. Pickworth W.B. Bunker E.B. Henningfield J.E. Transdermal nicotine: reduction of smoking with minimal abuse liability Psychopharmacology (Berl) 115 1994 9-14
8. Heishman S.J. Henningfield J.E. Singleton E.G. Tobacco, nicotine, and human cognition Nicotine Tob Res 4 2002 3-4
9. Provost S.C. Woodward R. Effects of nicotine gum on repeated administration of the Stroop test Psychopharmacology (Berl) 104 1991 536-540
10. Rusted J. Graupner L. O'Connell N. Nicholls C. Does nicotine improve cognitive function? Psychopharmacology (Berl) 115 1994 547-549
11. Wesnes K. Revell A. The separate and combined effects of scopolamine and nicotine on human information processing Psychopharmacology (Berl) 84 1984 5-11
12. Warburton D.M. Arnall C. Improvements in performance without nicotine withdrawal Psychopharmacology (Berl) 115 1994 539-542
13. Bell S.L. Taylor R.C. Singleton E.G. Henningfield J.E. Heishman S.J. Smoking after nicotine deprivation enhances cognitive performance and decreases tobacco craving in drug abusers Nicotine Tob Res 1 1999 45-52
14. Knott V. Bosman M. Mahoney C. Ilivitsky V. Quirt K. Transdermal nicotine: single dose effects on mood, EEG, performance, and event-related potentials Pharmacol Biochem Behav 63 1999 253-261
15. Davranche K. Audiffren M. Effects of a low dose of transdermal nicotine on information processing Nicotine Tob Res 4 2002 275-285
16. Cook M. Gerkovich M.M. Graham C. Hoffman S.J. Peterson R.C. Effects of the nicotine patch on performance during the first week of smoking cessation Nicotine Tob Res 5 2003 169-180
17. Sakurai Y. Kanazawa I. Acute effects of cigarettes in non-deprived smokers on memory, calculation and executive functions Hum Psychopharmacol 17 2002 369-373
18. Ernst M. Heishman S.J. Spurgeon L. London E.D. Smoking history and nicotine effects on cognitive performance Neuropsychopharmacology 25 2001 313-319
19. Heishman S.J. Henningfield J.E. Tolerance to repeated nicotine administration on performance, subjective, and physiological responses in nonsmokers Psychopharmacology (Berl) 152 2000 321-333
20. Lawrence N.S. Ross T.J. Stein E.A. Cognitive mechanisms of nicotine on visual attention Neuron 36 2002 539-548
21. Ernst M. Matochik J.A. Heishman S.J. Van Horn J.D. Jons P.H. Henningfield J.E. London E.D. Effect of nicotine on brain activation during performance of a working memory task Proc Natl Acad Sci U S A 98 2001 4728-4733
22. Stapleton J.M. Gilson S.F. Wong D.F. Villemagne V.L. Dannals R.F. Grayson R.F. Henningfield J.E. London E.D. Intravenous nicotine reduces cerebral glucose metabolism: a preliminary study Neuropsychopharmacology 28 2003 765-772
23. Mumenthaler M.S. Yesavage J.A. Taylor J.L. O'Hara R. Friedman L. Lee H. Kraemer H.C. Psychoactive drugs and pilot performace: a comparison of nicotine, donepezil and alcohol effects Neuropsychopharmacology 28 2003 1366-1373
24. Newhouse P.A. Potter A. Kelton M. Corwin J. Nicotinic treatment of Alzheimer's disease Biol Psychiatry 49 2001 268-278
25. Dani J.A. Overview of nicotinic receptors and their roles in the central nervous system Biol Psychiatry 49 2001 166-174
26. Lee P.N. Smoking and Alzheimer's disease: a review of the available evidence Neuroepidemiology 13 1994 131-144
27. Tyas S.L. Are tobacco and alcohol use related to Alzheimer's disease? A critical assessment of the evidence and its implications Addict Biol 1 1996 237-254
28. Van Duijn C.M. de Knijff P. Wehnert A. De Voecht J. Bronzova J.B. Havekes L.M. Hofman A. Van Broeckhoven C. The apolipoprotein E epsilon 2 allele is associated with an increased risk of early-onset Alzheimer's disease and a reduced survival Ann Neurol 37 1995 605-610
29. Whitehouse P.J. Martino A.M. Antuono P.G. Lowenstein P.R. Coyle J.T. Price D.R. Kellar K.J. Nicotinic acetylcholine binding sites in Alzheimer's disease Brain Res 371 1986 146-151
30. 3H]nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal J Neurochem 47 1986 1948-1954
31. Nordberg A. Winblad B. Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains Neurosci Lett 72 1986 115-119
32. Ksir C. Hakan R.L. Kellar K.J. Chronic nicotine and locomotor activity: influences of exposure dose and test dose Psychopharmacology (Berl) 92 1987 25-29
33. Aubert I. Araujo D.M. Cecyre D. Robitaille Y. Gauthier S. Quirion R. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases J Neurochem 58 1992 529-541
34. Whiting P.J. Lindstrom J.M. Purfication and characterization of a nicotinic acetylcholine receptor from rat brain Proc Natl Acad Sci U S A 84 1987 595-599
35. Flores C.M. Rogers S.W. Pabreza L.A. Wolfe B.B. Kellar K.J. A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment Mol Pharmacol 41 1992 31-37
36. Musachio J.L. Villemagne V.L. Scheffel U. Stathis M. Finley P. Horti A. London E.D. Dannals R.F. [I-125/123]IPH: a radioiodinated analog of epibatidine for in vivo studies of nicotinic acetylcholine receptors Synapse 26 1997 392-399
37. Sihver W. Nordberg A. Langstrom B. Mukhin A.G. Koren A.O. Kimes A.S. London E.D. Development of ligands for in vivo imaging of cerebral nicotinic receptors Behav Brain Res 113 2000 143-157
38. 123I]5-I-A-85380 in healthy human subjects Eur J Nucl Med Mol Imaging 29 2002 183-190
39. Horti A. Scheffel U. Stathis M. Finley P. Ravert H.T. London E.D. Dannals R.F. Fluorine-18-FPH for PET imaging of nicotinic acetylcholine receptors J Nucl Med 38 1997 1260-1265
40. Molina P.E. Ding Y.S. Carroll F.I. Liang F. Volkow N.D. Pappas N. Kuhar M. Abumrad N. Gatley S.J. Fowler J.S. Fluoro-norchloroepibatidine: preclinical assessment of acute toxicity Nucl Med Biol 24 1997 743-747
41. Sihver W. Fasth K.J. Horti A.G. Koren A.O. Bergstrom M. Lu L. Hagberg G. Lundqvist H. Dannals R.F. London E.D. et al. Synthesis and characterization of binding of 5-[76BR]bromo-3-[[2(S)-azetidinyl]methoxy]pyridine, a novel nicotinic acetylcholine receptor ligand, in rat brain J Neurochem 73 1999 1264-1272
42. Fan H. Scheffel U.A. Rauseo P. Xiao Y. Dogan A.S. Yokoi F. Hilton J. Kellar K.J. Wong D.F. Musachio J.L. Structure-in vivo activity of [I-125/123] 5-iodo-3-pyridyl ethers as potential nicotinic acetylcholine receptor tracers Nucl Med Biol 28 2001 911-921
43. Crook T. Bartus T. Ferris S. Whitehouse P. Age associated memory impairment: proposed diagnostic criteria and measures of clinical change-report of a National Institute of Mental Health Work Group Perspect Dev Neurobiol 2 1986 261-276
44. Dawe B. Procter A. Philpot M. Concepts of mild memory impairment in the elderly and their relationship to dementia: a review Int J Geriatr Psychiatry 7 1992 473-479
45. Petersen R. Normal aging, mild cognitive impairment, and early Alzheimer's disease Neurolog 1 1995 326-344
46. Petersen R.C. Doody R. Kurz A. Mohs R.C. Morris J.C. Rabins P.V. Ritchie K. Rossor M. Thal L. Winblad B. Current concepts in mild cognitive impairment Arch Neurol 58 2001 1985-1992
47. Petersen R. Smith G. Waring S. Ivnik R. Mild cognitive impairment: clinical characterization and outcome Arch Neurol 56 1999 303-308
48. Morris J.C. Storandt M. Miller J.P. McKeel D.W. Price J.L. Rubin E.H. Berg L. Mild cognitive impairment represents early-stage Alzheimer disease Arch Neurol 58 2001 397-405
49. White H, Levin E: Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment. Psychopharmacology, in press.
50. Newhouse P.A. Sunderland T. Tariot P.N. Blumhardt C.L. Weingartner H. Mellow A. Murphy D.L. Intravenous nicotine in Alzheimer's disease: a pilot study Psychopharmacology (Berl) 95 1988 171-175
51. Jones G.M.M. Sahakian B.J. Levy R. Warburton D.M. Gray J.A. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease Psychopharmacology (Berl) 108 1992 485-494
52. Sahakian BJ, Jones GMM: The effects of nicotine on attention, information processing, and working memory in patients with dementia of the Alzheimer type. In Effects of Nicotine on Biological Systems. Edited by Adlkofer F, Thruau K. Basel: Birkhauser Verlag; 1991:623.
53. Wilson A.L. Langley L.K. Monley J. Bauer T. Rottunda S. McFalls E. Kovera C. McCarten J.R. Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety Pharmacol Biochem Behav 51 1995 509-514
54. Newhouse P.A. Potter A. Corwin J. Lenox R. Acute nicotinic blockade produces cognitive impairment in normal humans Psychopharmacology (Berl) 108 1992 480-484
55. White H.K. Levin E.D. Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease Psychopharmacology (Berl) 143 1999 158-165
56. Snaedal J. Johannesson T. Jonsson J.E. Gylfadottir G. The effects of nicotine in dermal plaster on cognitive functions in patients with Alzheimer's disease Dementia 7 1996 47-52
57. Knott V. Mohr E. Engeland C. Ilivitsky V. Effects of acute nicotine administration on cognitive event-related potentials in tacrine-treated and non-treated patients with Alzheimer's disease Neuropsychobiology 45 2002 156-160
58. Potter A. Corwin J. Lang J. Piasecki M. Lenox R. Newhouse P. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease Psychopharmacology (Berl) 142 1999 334-342
59. McGehee D.S. Role L.W. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons Annu Rev Physiol 57 1995 521-546
60. Shimohama S. Taniguchi T. Fujiwara M. Kameyama M. Changes in nicotinic and muscarinic receptors in Alzheimer-type dementia J Neurochem 46 1986 288-293
61. Akaike A. Tamura Y. Yokota T. Shimohama S. Kimura J. Nicotine-induced protection of cultured cortical neurons against N-methyl-d-aspartate receptor-mediated glutamate cytotoxicity Brain Res 644 1994 181-187
62. Schwartz R.D. Kellar K.J. Nicotinic cholinergic binding sites in the brain: in vivo regulation Science 220 1983 214-216
63. 3H]-acetylcholine recognition sites in brain by nicotinic cholinergic drugs J Neurochem 45 1985 427-433
64. Whitehouse P. Hedreen J. White C. Basal forebrain neurons in dementia of Parkinson's disease Ann Neurol 13 1983 243-248
65. 3H] nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: an autoradiographic study Neurology 38 1988 720-723
66. 3H]acetylcholine on catecholamine and serotonin axons in brain J Neurochem 42 1984 1495-1498
67. Quik M. Kulak J.M. Nicotine and nicotinic receptors; relevance to Parkinson's disease Neurotoxicology 23 2002 581-594
68. Newhouse P.A. Potter A. Lenox R. The effects of nicotinic agents on human cognition: possible therapeutic applications in Alzheimer's and Parkinson's diseases Med Chem Res 2 1993 628-642
69. Newhouse P.A. Potter A. Levin E.D. Nicotinic system involvement in Alzheimer's and Parkinson's diseases: implications for therapeutics Drugs Aging 11 1997 206-228
70. Morens D.M. Grandinetti A. Reed D. White L.R. Ross G.W. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 45 1995 1041-1051
71. Gorell J.M. Rybicki B.A. Johnson C.C. Peterson E.L. Smoking and Parkinson's disease Neurology 52 1999 115-119
72. Perry E. Martin-Ruiz C. Lee M. Griffiths M. Johnson M. Piggott M. Haroutunian V. Buxbaum J.D. Nasland J. Davis K. et al. Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases Eur J Pharmacol 393 2000 215-222
73. Moll H. The treatment of post encephalitic Parkinsonism by nicotine Br Med J 1 1926 1079-1081
74. Fagerström K.O. Pomerleau O. Giordani B. Stelson F. Nicotine may relieve symptoms of Parkinson's disease Psychopharmacology (Berl) 116 1994 117-119
75. Kelton M.C. Kahn H.J. Conrath C.L. Newhouse P.A. The effects of nicotine on Parkinson's disease Brain Cogn 43 2000 274-282
76. Clemens P. Baron J.A. Coffey D. Reeves A. The short-term effect of nicotine chewing gum in patients with Parkinson's disease Psychopharmacology (Berl) 117 1995 253-256
77. Mitsuoka T. Kaseda Y. Yamashita H. Kohriyama T. Kawakami H. Nakamura S. Yamamura Y. Effects of nicotine chewing gum on UPDRS score and P300 in early-onset parkinsonism Hiroshima J Med Sci 51 2002 33-39
78. Sacaan A.I. Reid R.T. Santori E.M. Adams P. Correa L.D. Mahaffy L.S. Bleicher L. Cosford N. Stauderman K.A. McDonald I.A. et al. Pharmacological characterization of SIB-1765F: a novel cholinergic ion channel agonist J Pharmacol Exp Ther 280 1997 373-383
79. Menzaghi F. Whelan K.T. Risbrough V.B. Rao T.S. Lloyd G. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats J Pharmacol Exp Ther 280 1997 393-401
80. Schneider J. Van Velson M. Menzaghi F. Lloyd G. Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment Ann Neurol 43 1998 311-317
81. Rezwani A. Levin E. Cognitive effects of nicotine Biol Psychiatry 49 2001 258-267
82. Picciotto M.R. Caldarone B.J. King S.L. Zachariou V. Nicotine receptors in the brain: links between molecular biology and behavior Neuropsychopharmacology 22 2000 451-465
83. Glassman A.H. Cigarette smoking: implications for psychiatric illness Am J Psychiatry 150 1993 546-553
84. Adler L.E. Hoffer L.D. Wiser A. Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients Am J Psychiatry 150 1993 1856-1861
85. Nagamoto H.T. Adler L.E. Hea R.A. Griffith J.M. McRae K.A. Freedman R. Gating of auditory P50 in schizophrenics: unique effects of clozapine Biol Psychiatry 40 1996 181-188
86. Freedman R. Coon H. Myles-Worsley M. Orr-Urtreger A. Olincy A. Davis A. Polymeropoulos M. Holik J. Hopkins J. Hoff M. et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus Proc Natl Acad Sci U S A 94 1997 587-592
87. Freedman R. Hall M. Adler L.E. Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia Biol Psychiatry 38 1995 22-33
88. Leonard S. Gault J. Hopkins J. Logel J. Vianzon R. Short M. Drebing C. Berger R. Venn D. Sirota P. et al. Association of promoter variants in the α7 nicotine acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia Arch Gen Psychiatry 59 2002 1085-1096
89. Feldon J. Weiner I. From an animal model of an attentional deficit towards new insights into the pathophysiology of schizophrenia J Psychiatr Res 26 1992 345-366
90. Della Casa V. Hofer I. Weiner I. Feldon J. Effects of smoking status and schizotypy on latent inhibition J Psychopharmacol 13 1999 45-57
91. George T. Vessicchio J. Sahady D. Head C. Termine A. Bregartner T. Kosten T. Wexler B. Effects of smoking abstinence on cognitive function in schizophrenia Biol Psychiatry 49 2001 5S
92. Levin E. Wilson W. Rose J. McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics Neuropsychopharmacology 15 1996 429-436
93. Smith R.C. Singh A. Infante M. Khandat A. Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia Neuropsychopharmacology 27 2002 479-497
94. Pomerleau O.F. Downey K.K. Stelson F.W. Pomerleau C.S. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder J Subst Abuse 7 1995 373-378
95. Lambert N.M. Hartsough C.S. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants J Learn Disabil 31 1998 533-544
96. Levin E.D. Conners C.K. Sparrow E. Hinton S.C. Erhardt D. Meck W.H. Rose J.E. March J. Nicotine effects on adults with attention-deficit/hyperactivity disorder Psychopharmacology (Berl) 123 1996 55-63
97. Levin E.D. Conners C.K. Silva D. Canu W. March J. Effects of chronic nicotine and methylphenidate in adults with ADHD Exp Clin Psychopharmacol 9 2001 83-90
98. Wilens T.E. Biederman J. Spencer T.J. Bostic J. Prince J. Monuteaux M.C. Soriano J. Fine C. Abrams A. Rater M. Polisner D. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder Am J Psychiatry 156 1999 1931-1937
99. van der Meere J. Gunning B. Stemerdink N. The effect of methylphenidate and clonidine on response inhibition and state regulation in children with ADHD J Child Psychol Psychiatry 40 1999 291-298
100. Schachar R. Tannock R. Logan G. Inhibitory control, impulsiveness, and attention deficit hyperactivity disorder Clin Psychol Rev 13 1993 721-739
101. Barkley R.A. Attention-deficit/hyperactivity disorder, self-regulation, and time: toward a more comprehensive theory J Dev Behav Pediatr 18 1997 271-279
102. Potter A.S. Newhouse P.A. The effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder (ADHD) Biol Psychiatry 53 2003 83S
103. Wonnacott S. Soliakov L. Wilkie G. Redfern P. Marshall D. Presynaptic nicotinic acetylcholine receptors in the brain Drug Dev Res 38 1996 149-159
104. Rapier C. Lunt G.G. Wonnacott S. Nicotinic modulation of [3H]dopamine release from striatal synaptosomes: pharmacological characterisation J Neurochem 54 1990 937-945
105. Clarke P.B.S. Hommer D.W. Pert A. Skirboll L.R. Electrophysiological actions of nicotine on substantia nigra single units Br J Pharmacol 85 1985 827-835
106. Levin E.D. McGurk S.R. Rose J.E. Butcher L.L. Cholinergic-dopaminergic interactions in cognitive performance Behav Neural Biol 54 1990 271-299
107. Solanto M.V. Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research Behav Brain Res 130 2002 65-71
108. Perkins K.A. Baseline-dependency of nicotine effects: a review Behav Pharmacol 10 1999 597-615
109. Warburton D.M. Rusted J.M. Cholinergic control of cognitive resources Neuropsychobiology 28 1993 43-46
110. Baddeley A. Working memory: looking back and looking forward Nat Rev Neurosci 4 2003 829-839